Watson Pharma Starts New Era As Generic Drug Titan
Generic-drug maker Watson Pharmaceuticals started off its November with a bang: beating third-quarter estimates, hitting a new high on the stock market and starting a new life as a transformed company. Late on Oct. 31, Watson (WPI) announced it has closed its $5.9 billion acquisition of Swiss partner Actavis, making it the world's third-largest generic-drug maker after Teva Pharmaceutical Industries (TEVA) and Novartis (NVS) unit Sandoz. The firm
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here